Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CKD-504 in Healthy Volunteers
NCT03713892Phase 1Unknown
- Sponsor
- Chong Kun Dang Holdings
- Start
- May 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Huntington disease (HD) comparing CKD-504 with Placebo (2 arms). Primary endpoints: Maximum Plasma Concentration of CKD-504 at Day 4 and Area Under the Curve of CKD-504 at Day 4. Status: unknown.
02
Drugs
CKD-504
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NCT03713892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713892.